Combining drug-disease and economic modelling to inform drug development decisions

被引：27
|
作者：
Poland, B [1 ]
Wada, R [1 ]
机构：
[1] Pharsight Corp, Mt View, CA 94040 USA
来源：
DRUG DISCOVERY TODAY | 2001年 / 6卷 / 22期
关键词：
D O I：
10.1016/S1359-6446(01)02014-1
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Drug-disease models and clinical trial simulations are increasingly being used to support trial design and treatment optimization decisions. Less widely recognized is their potential for guiding strategic development decisions. These decisions require economic valuation of the potential product profile of efficacy, safety, ease of use, and so on. This review presents a disguised case study that uses drug-disease modelling to generate a probabilistic forecast of a drug's profile. This allows a quantitative analysis of whether to pursue a once-a-day regimen for an antiretroviral being tested twice-a-day in Phase II trials, and if so, at what dose and for which market segments.
引用
收藏
页码：1165 / 1170
页数：6
相关论文
共 50 条
  • [41] Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
    Liu, Hongrui
    Yu, Yiqun
    Guo, Nan
    Wang, Xiaojuan
    Han, Bing
    Xiang, Xiaoqiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [42] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
    Ruijuan Xu
    Weihong Ge
    Qing Jiang
    European Journal of Clinical Pharmacology, 2018, 74 : 755 - 765
  • [43] Preventable serious drug-disease interactions of reserve antibiotics
    Jankovic, Slobodan M.
    Jankovic, Snezana V.
    Stojadinovic, Dobrivoje
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2025,
  • [44] Drug-disease interaction in elderly patients in family practices
    Mand, Peter
    Roth, Katharina
    Biertz, Frank
    Kersting, Markus
    Kruschinski, Carsten
    Schmiemann, Guido
    Hummers-Pradier, Eva
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (05) : 337 - 345
  • [45] DEVELOPMENT OF A MECHANISM-BASED DRUG-DISEASE MODEL TO QUANTIFY POSTMENOPAUSAL OSTEOPOROSIS.
    Madrasi, K.
    Samant, S.
    Kim, M.
    Li, F.
    Voss, S.
    Kehoe, T.
    Schmidt, S.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S105 - S105
  • [46] In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects
    Xu, Xuan
    Riviere, Jim E.
    Raza, Shahzad
    Gedara, Nuwan Indika Millagaha
    Ramachandran, Remya Ampadi
    Tell, Lisa A.
    Wyckoff, Gerald J.
    Jaberi-Douraki, Majid
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (07) : 579 - 592
  • [47] Impact of Drug-Drug and Drug-Disease Interactions on Gait Speed in Community-Dwelling Older Adults
    Naples, J. G.
    Marcum, Z.
    Perera, S.
    Newman, A.
    Greenspan, S. L.
    Gray, S.
    Bauer, D.
    Simonsick, E. M.
    Shorr, R.
    Hanlon, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 : S110 - S110
  • [48] Impact of Drug-Drug and Drug-Disease Interactions on Gait Speed in Community-Dwelling Older Adults
    Naples, Jennifer G.
    Marcum, Zachary A.
    Perera, Subashan
    Newman, Anne B.
    Greenspan, Susan L.
    Gray, Shelly L.
    Bauer, Douglas C.
    Simonsick, Eleanor M.
    Shorr, Ronald I.
    Hanlon, Joseph T.
    DRUGS & AGING, 2016, 33 (06) : 411 - 418
  • [49] A tandem white shark algorithm approach for optimizing drug-disease and drug-drug interactions in multimorbidity and polypharmacy
    Al Khatib, Sultan M.
    BIOMEDICAL SIGNAL PROCESSING AND CONTROL, 2024, 87
  • [50] Risk of drug-disease and disease-drug interactions with anticonvulsants in HIV-positive patients - Reply
    Tseng, ALI
    Foisy, MM
    ANNALS OF PHARMACOTHERAPY, 1999, 33 (12) : 1373 - 1374
12345